HAE - Haemonetics Corporation
After hours:
Chart Events
Intermediate-term KST
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 88.13 |
| Open | 87.21 |
| Bid | 83.62 x 1400 |
| Ask | 89.37 x 800 |
| Day's Range | 86.13 - 87.70 |
| 52 Week Range | 58.23 - 91.39 |
| Volume | |
| Avg. Volume | 300,714 |
| Market Cap | 4.369B |
| Beta (5Y Monthly) | 0.44 |
| PE Ratio (TTM) | 36.94 |
| EPS (TTM) | 2.34 |
| Earnings Date | Aug 08, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 105.29 |
Fair Value
Related Research
ZacksEarnings Estimates Moving Higher for Haemonetics (HAE): Time to Buy?
Haemonetics (HAE) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
ZacksWalgreens Boots (WBA) Gains From New Alliances Amid Macro Woes
Continued slowdown in generic introduction has been affecting Walgreens Boots' (WBA) margins.
ZacksNeogen (NEOG) Introduces 2 Assays for Histamine Detection
Neogen (NEOG) launches Reveal for Histamine and Reveal Q+ for Histamine assays for the detection of Histamine.
ZacksHaemonetics (HAE) Hospital Arm Grows, Plasma Volume Improves
Within Haemonetics (HAE) Vascular Closure, growth is led by the opening of new accounts and increasing penetration to gain share in the top U.S. EP hospitals.
ZacksAre Medical Stocks Lagging Alimera Sciences (ALIM) This Year?
Here is how Alimera Sciences (ALIM) and Haemonetics (HAE) have performed compared to their sector so far this year.
- Zacks
Here's Why You Should Invest in Haemonetics (HAE) Right Now
Investors are optimistic about Haemonetics (HAE), led by the impressive performance of Plasma and Hospital businesses.
ZacksHere's Why Haemonetics (HAE) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ZacksHow Much Upside is Left in Haemonetics (HAE)? Wall Street Analysts Think 27.09%
The mean of analysts' price targets for Haemonetics (HAE) points to a 27.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ZacksNew Strong Buy Stocks for May 26th
HDELY, WIRE, HAE, GWW and MUSA have been added to the Zacks Rank #1 (Strong Buy) List on May 26, 2023.
ZacksHAE or PODD: Which Is the Better Value Stock Right Now?
HAE vs. PODD: Which Stock Is the Better Value Option?
Simply Wall St.Is Weakness In Haemonetics Corporation (NYSE:HAE) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
With its stock down 6.0% over the past week, it is easy to disregard Haemonetics (NYSE:HAE). However, stock prices are...
ZacksIs Apyx Medical (APYX) Stock Outpacing Its Medical Peers This Year?
Here is how Apyx Medical (APYX) and Haemonetics (HAE) have performed compared to their sector so far this year.
ZacksHaemonetics (HAE) Q4 Earnings and Revenues Top Estimates
Amid a challenging economic environment, Haemonetics (HAE) delivers impressive fiscal fourth-quarter organic revenues, led by the stellar performance across the Plasma and Hospital business.
ZacksHere's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings
While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
PR NewswireHaemonetics 4th Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website
Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal 2023, which ended April 1, 2023, are available on its Investor Relations website.
ZacksVerano Holdings Corp. (VRNOF) Reports Q1 Loss, Tops Revenue Estimates
Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of 57.14% and 0.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksVREX or HAE: Which Is the Better Value Stock Right Now?
VREX vs. HAE: Which Stock Is the Better Value Option?
- PR Newswire
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2023 Results: May 11, 2023
Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2023 financial results at 6:00 am ET on Thursday, May 11, 2023. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 11, 2023.
- PR Newswire
Haemonetics Publishes Inaugural Corporate Responsibility Report
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced the release of its 2022 Corporate Responsibility Report. The report outlines key environmental, social and governance (ESG) initiatives of Haemonetics that align with its core values and corporate strategy.
ZacksHAE vs. SYK: Which Stock Is the Better Value Option?
HAE vs. SYK: Which Stock Is the Better Value Option?
ZacksIs Butterfly Network (BFLY) Stock Outpacing Its Medical Peers This Year?
Here is how Butterfly Network, Inc. (BFLY) and Haemonetics (HAE) have performed compared to their sector so far this year.
ZacksWhy This 1 Value Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks4 Low-Beta Stocks to Buy to Endure Market Volatility
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Haemonetics (HAE), The Kroger Co. (KR), JOYY (YY) and Novo Nordisk (NVO) are poised to gain.
ZacksAngioDynamics (ANGO) Q3 Earnings Lag Estimates, FY23 View Cut
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in third-quarter fiscal 2023.
ZacksTeleflex (TFX) Urolift Market Expansion Strong, Cost Woe Stays
Teleflex (TFX) plans to spend 2023 training surgeons, building its presence in key cities and continuing to engage with the Chinese Urological Society to build acceptance.
